Preclinical atherosclerosis in patients with prolactinoma

Endocrine Practice

Volumn 20, Issue 5, 2014, Pages 447-451

  Arslan, Muyesser ^a   Topaloglu, Oya ^a   Sahin, Mustafa ^b   Tutal, Esra ^a   Gungunes, Askin ^a   Cakir, Evrim ^a   Ozturk, Ilknur ^a   Karbek, Basak ^a   Ucan, Bekir ^a   Ginis, Zeynep ^a   Cakal, Erman ^a   Ozbek, Mustafa ^a   Delibasi, Tuncay ^a,c  

^a DISKAPI YILDIRIM BEYAZIT TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b ANKARA UNIVERSITY   (Turkey)

^c HACETTEPE UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; FATTY ACID BINDING PROTEIN; GLUCOSE; HEART TYPE FATTY ACID BINDING PROTEIN; HIGH SENSITIVITY C REACTIVE PROTEIN; INSULIN; LIPID; PROLACTIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ABDOMINAL FAT; ADULT; ARTERIAL WALL THICKNESS; ARTICLE; B SCAN; BIOELECTRICAL IMPEDANCE ANALYSIS; BODY FAT; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAROTID ATHEROSCLEROSIS; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLUCOSE BLOOD LEVEL; HIP CIRCUMFERENCE; HOMEOSTASIS; HUMAN; HYPERPROLACTINEMIA; HYPOPHYSIS ADENOMA; IMPEDANCE; INFLAMMATION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTRAABDOMINAL FAT; LIPID ANALYSIS; LIPID BLOOD LEVEL; MALE; MIDDLE AGED; PREDICTIVE VALUE; PROLACTIN BLOOD LEVEL; PROLACTINOMA; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; TRIACYLGLYCEROL BLOOD LEVEL; TRUNK; WAIST CIRCUMFERENCE; ATHEROSCLEROSIS; BLOOD; COMPLICATION;

ADULT; ATHEROSCLEROSIS; CAROTID INTIMA-MEDIA THICKNESS; FATTY ACID-BINDING PROTEINS; FEMALE; HUMANS; INSULIN RESISTANCE; MALE; MIDDLE AGED; PROLACTINOMA;

EID: 84900390773     PISSN: 1530891X     EISSN: 19342403     Source Type: Journal    
DOI: 10.4158/EP13173.OR     Document Type: Article

References (33)

1. Creemers LB, Zelissen PM, Van't Verlaat JW,Koppeschaar HP. Prolactinoma and body weight: a retrospectivestudy. Acta Endocrinol (Copenh). 1991;125;392-396.
2. Shibli-Rahhal A, Schlechte J. The effects of hyperprolactinemiaon bone and fat. Pituitary. 2009;12: 96-104.
3. Serri O, Beauregard H, Rasio E, Hardy J. Decreasedsensitivity to insulin in women with microprolactinomas.Fertil Steril.1986;45:572-574.
4. Pelkonen R, Nikkilä EA, Grahne B. Serum lipids, postheparinplasma lipase activities and glucose tolerance inpatients with prolactinoma. Clin Endocrinol (Oxf). 1982;16,383-390.
5. Erem C, Kocak M, Nuhoglu I, Y?lmaz M, UcuncuO. Blood coagulation, fibrinolysis and lipid profile inpatients with prolactinoma. Clin Endocrinol (Oxf). 2010;73;502-527.
6. Serri O, Li L, Mamputu JC, Beauchamp MC, MaingretteF, Renier G. The influences of hyperprolactinemia andobesity on cardiovascular risk markers: effects of cabergolinetherapy. Clin Endocrinol (Oxf). 2006;64:366-370.
7. Georgiopoulos GA, Stamatelopoulos KS,Lambrinoudaki I, et al. Prolactin and preclinical atherosclerosisin menopausal women with cardiovascular riskfactors. Hypertension. 2009;54:98-105.
8. Reuwer AQ, Twickler MT, Hutten BA, et al. Prolactinlevels and the risk of future coronary artery disease inapparently healthy men and women. Circ CardiovascGenet. 2009;2: 389-395.
9. Yu-Lee LY. Prolactin modulation of immune and inflammatoryresponses. Recent Prog Horm Res. 2002;57:435-455.
10. Montes de Oca P, Macotela Y, Nava G, López-BarreraF, de la Escalera GM, Clapp C. Prolactin stimulates integrin-mediated adhesion of circulating mononuclear cells toendothelial cells. Lab Invest. 2005;85:633-642.
11. Sauro MD, Buckley AR, Russell DH, Fitzpatrick DF.Prolactin stimulation of protein kinase C activity in rat aorticsmooth muscle. Life Sci. 1989;44:1787-1792.
12. Molinari C, Grossini E, Mary DA, et al. Prolactin inducesregional vasoconstriction through the beta2-adrenergicand nitric oxide mechanisms. Endocrinology. 2007;148:4080-4090.
13. Yavuz D, Deyneli O, Akpinar I. Endothelial function,insulin sensitivity and inflammatory markers in hyperprolactinemicpre-menopausal women. Eur J Endocrinol.2003;149:187-193.
14. Karaduman M, Sengul A, Oktenli C, et al. Tissue levelsof adiponectin, tumour necrosis factor-alpha, solubleintercellular adhesion molecule-1 and heart-type fatty acidbindingprotein in human coronary atherosclerotic plaques.Clin Endocrinol (Oxf). 2006;64:196-202.
15. Ghani F, Wu AH, Graff L, Petry C, et al. Role of hearttypefatty acid-binding protein in early detection of acutemyocardial infarction. Clin Chem. 2000;46;718-719.
16. Komamura K, Sasaki T, Hanatani A, et al. Heart-typefatty acid binding protein is a novel prognostic markerin patients with non-ischaemic dilated cardiomyopathy.Heart. 2006;92:615-618.
17. Akbal E, Ozbek M, Günes F, Akyürek Ö, Üreten K,Deliba T. Serum heart type fatty acid binding protein levelsin metabolic syndrome. Endocrine. 2009;36:433-437.
18. Dellas C, Puls M, Lankeit M, et al. Elevated heart-typefatty acid-binding protein levels on admission predict anadverse outcome in normotensive patients with acute pulmonaryembolism. J Am Coll Cardiol. 2010;55:2150-2157.
19. Mancini GB, Dahlöf B, Díez J. Surrogate markers for cardiovasculardisease: structural markers. Circulation. 2004;109:IV22-30.
20. Matthews DR, Hosker JP, Rudenski AS, Naylor BA,Treacher DF, Turner RC. Homeostasis model assessment:insulin resistance and beta-cell function from fasting bloodglucose and insulin concentrations in man. Diabetologia.1985;28: 412-419.
21. Thomas EL, Collins AL, McCarthy J, et al. Estimationof abdominal fat compartments by bioelectrical impedance:the validity of the ViScan measurement system in comparisonwith MRI. Eur J Clin Nutr. 2010;64:525-533.
22. Shelly S, Boaz M, Orbach H. Prolactin and autoimmunity.Autoimmun Rev. 2012;11:A465-470.
23. Clapp C, López-Gómez FJ, Nava G, et al. Expressionof prolactin mRNA and of prolactin-like proteins in endothelialcells: evidence for autocrine effects. J Endocrinol.1998;158:137-144.
24. Reuwer AQ, van Eijk M, Houttuijn-Bloemendaal FM,et al. The prolactin receptor is expressed in macrophageswithin human carotid atherosclerotic plaques: a role for prolactinin atherogenesis? J Endocrinol. 2011;208;107-117.
25. Zeiher AM, Drexler H, Wollschläger H, Just H.Endothelial dysfunction of the coronary microvasculatureis associated with coronary blood flow regulation inpatients with early atherosclerosis. Circulation. 1991;84:1984-1992.
26. Pignoli P, Tremoli E, Poli A, Oreste P, Paoletti R. Intimalplus medial thickness of the arterial wall: a direct measurementwith ultrasound imaging. Circulation. 1986;74:1399-1406.
27. de Groot E, Hovingh GK, Wiegman A, et al. Measurementof arterial wall thickness as a surrogate marker for atherosclerosis.Circulation. 2004;109:III33-38.
28. Burton PB, Hogben CE, Joannou CL, et al. Heart fattyacid binding protein is a novel regulator of cardiac myocytehypertrophy. Biochem Biophys Res Commun. 1994;205:1822-1828.
29. Manku MS, Horrobin DF, Zinner H, et al. Dopamineenhances the action of prolactin on rat blood vessels.Implications for dopamine effects on plasma prolactin.Endocrinology. 1977;101:1343-1345.
30. Ridker PM, Hennekens CH, Buring JE, Rifai N.C-reactive protein and other markers of inflammation inthe prediction of cardiovascular disease in women. N EnglJ Med. 2000;342;836-843.
31. Ling C, Svensson L, Odén B, et al. Identification offunctional prolactin (PRL) receptor gene expression: PRLinhibits lipoprotein lipase activity in human white adiposetissue. J Clin Endocrinol Metab. 2003;88:1804-1808.
32. Naliato EC, Violante AH, Caldas D, et al. Body fat innonobese women with prolactinoma treated with dopamineagonists. Clin Endocrinol (Oxf). 2007;67:845-852.
33. dos Santos Silva CM, Barbosa FR, Lima GA,Warszawski L, et al. BMI and metabolic profile in patientswith prolactinoma before and after treatment with dopamineagonists. Obesity (Silver Spring). 2011;19:800-805.